StreetInsider.com News Articles

Invivyd presents measles antibody candidate VMS063 at IDWeek 2026

Wed, 21 Oct 2026 07:04:04 -0400

Invivyd, Inc. (Nasdaq: IVVD) presented preclinical data on VMS063, its investigational monoclonal antibody candidate for measles treatment and prevention, at IDWeek 2026 in Washington, D.C., on Oct. 21.

The company says VMS063 demonstrated potent in vitro antiviral activity against contemporary measles virus variants, including the most widely circulating genotypes B3 and D8, in both authentic virus and pseudovirus neutralization assays. The candidate targets the measles fusion protein, locking it in a pre-fusion configuration to inhibit cell entry.

There are currently no FDA-approved treatments for measles. Invivyd said it intends to develop VMS063 in either intramuscular or subcutaneous forms and has begun manufacturing

Invivyd Presents VMS063, a Potential Best-in-Class Monoclonal Antibody Candidate for the Treatment and Prevention of Measles, at IDWeek 2026

Wed, 21 Oct 2026 07:01:00 -0400

VMS063 is a novel, potential first- and best-in-class monoclonal antibody investigational candidate discovered by Invivyd
VMS063 demonstrated potent in vitro antiviral activity against contemporary measles virus variants, and attractive biophysical properties supporting its potential utility for both treatment and prevention of measles
Invivyd is scaling up production toward clinical development in 2027
There are currently no FDA approved treatments for measles, leaving a major gap in the public health and medical management of measles
The U.S. is experiencing a record-breaking number of measles cases in 2026, and a significant immunity gap has emerged, leaving millions of Americans vulnerable to measles infection and associated

Invivyd Presents VMS063, a Potential Best-in-Class Monoclonal Antibody Candidate for the Treatment and Prevention of Measles, at IDWeek 2026

Wed, 21 Oct 2026 07:01:00 -0400

VMS063 is a novel, potential first- and best-in-class monoclonal antibody investigational candidate discovered by Invivyd
VMS063 demonstrated potent in vitro antiviral activity against contemporary measles virus variants, and attractive biophysical properties supporting its potential utility for both treatment and prevention of measles
Invivyd is scaling up production toward clinical development in 2027
There are currently no FDA approved treatments for measles, leaving a major gap in the public health and medical management of measles
The U.S. is experiencing a record-breaking number of measles cases in 2026, and a significant immunity gap has emerged, leaving millions of Americans vulnerable to measles infection and associated

Invivyd starts Phase 2 trial of VYD2311 for Long COVID treatment

Wed, 14 Oct 2026 07:01:16 -0400

Invivyd, Inc. (Nasdaq: IVVD) and the SPEAR Study Group announced the initiation of FLINTLOCK, a Phase 2 clinical trial evaluating monoclonal antibody VYD2311 in adults with Long COVID or Post-Vaccination Syndrome (PVS), according to a press release dated Oct. 14, 2026.

The randomized, double-blind, placebo-controlled study will enroll approximately 130 participants aged 18 to 65 years who have at least two persistent symptoms following a COVID-19 infection or COVID-19 vaccination. Participants must have had symptoms for six months or more.

The trial will administer a high-dose intravenous infusion of VYD2311 on Day 1, followed by intramuscular injections on Day 30 and Day

Invivyd and the SPEAR Study Group Announce Initiation of “FLINTLOCK” Phase 2 Study of VYD2311, a Monoclonal Antibody for the Potential Treatment of Long COVID or Post-Vaccination Syndrome

Wed, 14 Oct 2026 07:01:00 -0400

FLINTLOCK Phase 2 clinical trial will evaluate the safety, tolerability, pharmacokinetics, and clinical efficacy of high-dose monoclonal antibody VYD2311 in adults aged 18-65 years with Long COVID or Post-Vaccination Syndrome, also known as COVID vaccine injury
Design includes VYD2311 administered in three doses to assess the safety and potential clinical benefit of VYD2311 treatment versus placebo over 90 days
VYD2311 has demonstrated high in vitro antiviral potency across all SARS-CoV-2 variants tested from original Wuhan through contemporary Omicron variants
FLINTLOCK is part of Invivyd’s broader REVOLUTION clinical program for VYD2311, including DECLARATION and LIBERTY
Millions of individuals continue to live with persistent and

Invivyd and the SPEAR Study Group Announce Initiation of “FLINTLOCK” Phase 2 Study of VYD2311, a Monoclonal Antibody for the Potential Treatment of Long COVID or Post-Vaccination Syndrome

Wed, 14 Oct 2026 07:01:00 -0400

FLINTLOCK Phase 2 clinical trial will evaluate the safety, tolerability, pharmacokinetics, and clinical efficacy of high-dose monoclonal antibody VYD2311 in adults aged 18-65 years with Long COVID or Post-Vaccination Syndrome, also known as COVID vaccine injury
Design includes VYD2311 administered in three doses to assess the safety and potential clinical benefit of VYD2311 treatment versus placebo over 90 days
VYD2311 has demonstrated high in vitro antiviral potency across all SARS-CoV-2 variants tested from original Wuhan through contemporary Omicron variants
FLINTLOCK is part of Invivyd’s broader REVOLUTION clinical program for VYD2311, including DECLARATION and LIBERTY
Millions of individuals continue to live with persistent and

Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mon, 05 Oct 2026 07:01:00 -0400

NEW HAVEN, Conn., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that on October 1, 2026, Invivyd granted six newly hired non-executive employees options to purchase an aggregate of 157,500 shares of its common stock, each as a material inducement for each employee’s entry into employment with Invivyd. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and pursuant to the Invivyd, Inc. 2026 Inducement Plan.

The options have a per share exercise price of $0.8165, representing the closing price of Invivyd’s common stock on the grant date. Each option vests over four years, with 25% of the shares

Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mon, 05 Oct 2026 07:01:00 -0400

NEW HAVEN, Conn., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that on October 1, 2026, Invivyd granted six newly hired non-executive employees options to purchase an aggregate of 157,500 shares of its common stock, each as a material inducement for each employee’s entry into employment with Invivyd. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and pursuant to the Invivyd, Inc. 2026 Inducement Plan.

The options have a per share exercise price of $0.8165, representing the closing price of Invivyd’s common stock on the grant date. Each option vests over four years, with 25% of the shares

H.C. Wainwright Reiterates Buy Rating on Invivyd Inc. (IVVD)

Wed, 30 Sep 2026 07:19:13 -0400

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating and $10.00 price target on Invivyd Inc. (NASDAQ: IVVD).
The analyst commented: "This morning, Invivyd announced that intramuscular VYD2311 met both LIBERTY co-primary safety and tolerability endpoints against COMIRNATY, a COVID-19 mRNA vaccine, including a lower six-day incidence of treatment-emergent adverse events (TEAEs), injection-site reactions, or hypersensitivity (56.5% vs 91.4%; p<0.0001) and fewer solicited systemic adverse events (44.1% vs 68.1%; p=0.008) (link to deck). Importantly, co-administration increased the total neutralizing titers from COVID-19 mRNA vaccine alone by approximately 2.5x over the 56-day trial without detectable interference with vaccine-induced titers. Overall, we view

Form 8-K Invivyd, Inc. For: Sep 29

Tue, 29 Sep 2026 07:27:00 -0400
si-local-file:///var/storage/secattach/20260929/27117375.html

Invivyd's VYD2311 shows fewer side effects than mRNA COVID vaccine

Tue, 29 Sep 2026 07:01:18 -0400

Invivyd, Inc. (Nasdaq: IVVD) reported topline results from its LIBERTY Phase 3 clinical trial on Sept. 29, 2026, showing that its investigational monoclonal antibody VYD2311 met all primary and secondary safety and tolerability endpoints when compared to an mRNA-based COVID-19 vaccine.

The study enrolled 210 healthy adults aged 18 to 49, randomized into three arms: VYD2311 alone, COMIRNATY mRNA-based COVID-19 vaccine alone, and a combination of both. In the six days following dosing, 56.5% of VYD2311 recipients experienced a treatment-emergent adverse event, injection site reaction, or hypersensitivity reaction, compared with 91.4% in the mRNA vaccine arm (p<0.0001). Systemic adverse events occurred

Invivyd Announces Positive Topline Results from LIBERTY Phase 3 Study Demonstrating VYD2311 Safety and Tolerability Superior to mRNA-based COVID-19 Vaccine; Announces Regulatory Submission Plans for V

Tue, 29 Sep 2026 07:01:00 -0400

VYD2311 met all primary and secondary endpoints comparing VYD2311 to an mRNA-based COVID-19 vaccine, demonstrating VYD2311 safety and tolerability that is clinically and statistically superior to the safety and tolerability of an mRNA-based COVID-19 vaccine
VYD2311 combined with an mRNA-based COVID-19 vaccine demonstrated no interference with vaccine-induced neutralizing titers, and instead added substantially to vaccine-induced neutralizing titers
VYD2311 observed profile in LIBERTY indicates high measured neutralizing antiviral titers supporting the target profile for VYD2311 under study in the DECLARATION pivotal clinical study
Invivyd plans for DECLARATION and LIBERTY clinical studies to be the basis of a planned Biologics License Application

Invivyd Announces Positive Topline Results from LIBERTY Phase 3 Study Demonstrating VYD2311 Safety and Tolerability Superior to mRNA-based COVID-19 Vaccine; Announces Regulatory Submission Plans for V

Tue, 29 Sep 2026 07:01:00 -0400

VYD2311 met all primary and secondary endpoints comparing VYD2311 to an mRNA-based COVID-19 vaccine, demonstrating VYD2311 safety and tolerability that is clinically and statistically superior to the safety and tolerability of an mRNA-based COVID-19 vaccine
VYD2311 combined with an mRNA-based COVID-19 vaccine demonstrated no interference with vaccine-induced neutralizing titers, and instead added substantially to vaccine-induced neutralizing titers
VYD2311 observed profile in LIBERTY indicates high measured neutralizing antiviral titers supporting the target profile for VYD2311 under study in the DECLARATION pivotal clinical study
Invivyd plans for DECLARATION and LIBERTY clinical studies to be the basis of a planned Biologics License Application

Invivyd to Participate in Upcoming September Investor Conferences

Tue, 08 Sep 2026 07:01:00 -0400

NEW HAVEN, Conn., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that Marc W. Elia, Chairman and Chief Executive Officer, and members of company management will participate in three upcoming investor conferences:

Citi’s 2026 Biopharma Back to School Conference
Wednesday, September 9, 2026 (Meetings Only)
Location: New York, NY

2026 Cantor Global Healthcare Conference
Fireside Chat: Thursday, September 10, 2026 at 9:45 AM ET (Webcast Link)
Meetings to Follow
Location: New York, NY

H.C. Wainwright 28^th Annual Global Investment Conference
Fireside Chat: Monday,

Invivyd to Participate in Upcoming September Investor Conferences

Tue, 08 Sep 2026 07:01:00 -0400

NEW HAVEN, Conn., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that Marc W. Elia, Chairman and Chief Executive Officer, and members of company management will participate in three upcoming investor conferences:

Citi’s 2026 Biopharma Back to School Conference
Wednesday, September 9, 2026 (Meetings Only)
Location: New York, NY

2026 Cantor Global Healthcare Conference
Fireside Chat: Thursday, September 10, 2026 at 9:45 AM ET (Webcast Link)
Meetings to Follow
Location: New York, NY

H.C. Wainwright 28^th Annual Global Investment Conference
Fireside Chat: Monday,

Invivyd names chairman Marc Elia as CEO ahead of VYD2311 data

Tue, 01 Sep 2026 07:02:47 -0400

Invivyd, Inc. (Nasdaq: IVVD) has appointed Marc W. Elia, its current Chairman of the Board of Directors, as Chief Executive Officer, according to a press release issued by the company. Elia will hold both the Chairman and CEO roles going forward.
Elia has served as Chairman of Invivyd's board since June 2022. Ajay Royan, founder of Mithril Capital and a long-term investor in Invivyd, has been appointed Lead Independent Director. Ian Sheffield, founder and Managing Partner of North Country Holdings, a private investment firm, has joined the board as an independent director. Sheffield has more than 20 years of experience as

Invivyd names chairman Marc Elia as CEO ahead of VYD2311 data

Tue, 01 Sep 2026 07:02:47 -0400

Invivyd, Inc. (Nasdaq: IVVD) has appointed Marc W. Elia, its current Chairman of the Board of Directors, as Chief Executive Officer, according to a press release issued by the company. Elia will hold both the Chairman and CEO roles going forward.
Elia has served as Chairman of Invivyd's board since June 2022. Ajay Royan, founder of Mithril Capital and a long-term investor in Invivyd, has been appointed Lead Independent Director. Ian Sheffield, founder and Managing Partner of North Country Holdings, a private investment firm, has joined the board as an independent director. Sheffield has more than 20 years of experience as

Invivyd Appoints Chairman Marc W. Elia as Chief Executive Officer; Approaches Results of VYD2311 studies DECLARATION and LIBERTY

Tue, 01 Sep 2026 07:01:00 -0400

Mr. Elia has served as Chairman of Invivyd’s Board of Directors since June of 2022; has architected Invivyd’s scientific and corporate strategy
Ajay Royan, Founder of Mithril Capital and a founding, long-term investor in Invivyd, appointed Lead Independent Director
Ian Sheffield appointed to Invivyd’s Board of Directors as an independent director
DECLARATION and LIBERTY studies of VYD2311 approaching completion with further updates expected within weeks

NEW HAVEN, Conn., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that the company has appointed Marc Elia, current Chairman of the Invivyd Board of Directors, as

Invivyd Appoints Chairman Marc W. Elia as Chief Executive Officer; Approaches Results of VYD2311 studies DECLARATION and LIBERTY

Tue, 01 Sep 2026 07:01:00 -0400

Mr. Elia has served as Chairman of Invivyd’s Board of Directors since June of 2022; has architected Invivyd’s scientific and corporate strategy
Ajay Royan, Founder of Mithril Capital and a founding, long-term investor in Invivyd, appointed Lead Independent Director
Ian Sheffield appointed to Invivyd’s Board of Directors as an independent director
DECLARATION and LIBERTY studies of VYD2311 approaching completion with further updates expected within weeks

NEW HAVEN, Conn., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that the company has appointed Marc Elia, current Chairman of the Invivyd Board of Directors, as

Invivyd Inc. (IVVD) Reiterated at Overweight by Cantor Fitzgerald

Thu, 27 Aug 2026 07:27:23 -0400

Cantor Fitzgerald analyst Josh Schimmer reiterated an Overweight rating and $10.00 price target on Invivyd Inc. (NASDAQ: IVVD).
The analyst commented, "Last week marked the launch of our weekly COVID tracker series. We're keeping a close eye on COVID trends, particularly given their relevance to IVVD's DECLARATION study, which is evaluating the monoclonal antibody VYD2311 for COVID prevention. The DECLARATION study is likely in its final weeks of patient data collection. We're seeing more hotspots emerge nationally, including in regions where IVVD has active clinical sites — a dynamic we view as a positive signal ahead of the upcoming data readout."
For

Form 4 Invivyd, Inc. For: Aug 15 Filed by: Duke William E.

Tue, 18 Aug 2026 20:10:00 -0400
si-local-file:///var/storage/secattach/20260818/26945984.html

Form 4 Invivyd, Inc. For: Aug 15 Filed by: Duke William E.

Tue, 18 Aug 2026 20:10:00 -0400
si-local-file:///var/storage/secattach/20260818/26945984.html

Form 4 Invivyd, Inc. For: Aug 15 Filed by: Lee Timothy Edward

Tue, 18 Aug 2026 20:10:00 -0400
si-local-file:///var/storage/secattach/20260818/26945983.html

Form 4 Invivyd, Inc. For: Aug 15 Filed by: Lee Timothy Edward

Tue, 18 Aug 2026 20:10:00 -0400
si-local-file:///var/storage/secattach/20260818/26945983.html

Form 4 Invivyd, Inc. For: Aug 15 Filed by: Green Julie

Tue, 18 Aug 2026 20:10:00 -0400
si-local-file:///var/storage/secattach/20260818/26945982.html